



Joseph Abate
+1 212 412 7459
joseph.abate@barclays.com
BCI, US

Money Markets Monthly Update

April 2020

This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242. Barclays trades the securities covered in this report for its own account and on a discretionary basis on behalf of certain clients. Such trading interests may be contrary to the recommendations offered in this report.

PLEASE SEE ANALYST CERTIFICATIONS AND IMPORTANT DISCLOSURES STARTING AFTER PAGE 49.

Summary

- Extraordinary measures:
 - Reserve expansion and asset purchases
 - Liquidity programs – tepid demand
 - Credit programs – ready to launch
- Bill issuance and rate effects
- CP market conditions – mending?
 - We look for LOIS to fall to 45bp in June and 25bp in September
 - Prime money fund balance stabilization

Extraordinary measures

COVID 19: The Fed's evolving response

1. Initially, the Fed moved to increase liquidity sharply
 - By rapidly expanding the level of bank reserves through asset purchases and open market operations
 - And removing Treasuries and agency MBS securities that were clogging up bank and dealer balance sheets
2. Next, it re-constituted some of its 2008 liquidity programs
 - To direct liquidity into the CP market and money funds
 - These programs rely on banks and dealers to take liquidity from the Fed and re-distribute it through the broader economy
3. Its most recent operations have focussed on getting liquidity more directly to end-users
 - Including small businesses and municipalities


The Fed resumed large-scale asset purchases...

- The Fed shifted to open-ended purchases of Treasuries and agency MBS last month
 - It added CMBS to its purchases as well
- Since mid-March, the Fed has purchased over \$1.3trn in Treasuries and more than \$650bn in MBS^{1/}

1/ As of April 15, the Fed held \$5.7bn in CMBS


...and sharply increased the level of bank reserves

TSY and MBS holdings (\$bn)



Source: Federal Reserve, Barclays Research


Bank reserves (\$bn)



Source: Federal Reserve, Barclays Research

Fed purchases have relieved balance sheet pressure


- The Fed's asset purchases have helped reduce some of the crowding on dealer balance sheets
 - That was creating distortions in the Treasury and MBS markets
- This, in turn, has increased the ability of banks and dealers to make markets
 - *And improved overall market liquidity*



Source: Federal Reserve, Barclays Research

But it has also created some other dislocations...

- However, the rapid purchase pace has created other market dislocations
 - Some Treasury issues have become hard to source in the market
 - And the volume of fails – or incomplete deliveries – has increased




Source: Federal Reserve, Barclays Research

...and pushed the fed funds rate closer to its lower boundary

- The sharp expansion in bank reserves has pushed the funds rate to within 5bp of the bottom band
- As reserve balances increase, so will the pressure on the funds rate
 - And the Fed may need to adjust the RRP rate higher^{1/}

Fed funds rate less bottom band (bp)




^{1/} See [Adjusting the RRP rate](#), April 6, 2020

Note: Month-ends excluded. Source: Federal Reserve, Barclays Research

The Fed has begun to taper its purchases...

Daily asset purchase pace (\$bn)




- Liquidity has improved in the Treasury and MBS markets
 - And the Fed has begun to slow its asset purchases
- *Could the Fed finish these 'liquidity' purchases by the end of May?*
 - *And shift to 'expansionary' or stimulus-driven purchases thereafter?*

Source: Federal Reserve, Barclays Research

Liquidity briefly started to puddle up in March


- RRP balances jumped as repo rates plunged to 0%
 - But as bill supply surged, repo rates moved off of zero
 - And RRP usage fell
- *Could RRP use swell once the Treasury starts to slow bill issuance?*
 - *As rising reserve balances push all overnight rates toward 0*



Source: Federal Reserve, Barclays Research

The Fed will begin to scale back its open market operations

Open market operations (\$bn)



- The Fed sharply increased its open market operations in order to bring repo rates down
 - Providing \$500bn in regular 1m and 3m operations
- But as market liquidity has improved, funding rates have fallen below the Fed's open market operation rates
 - *And program demand has ebbed^{1/}*

Source: Federal Reserve, Barclays Research

^{1/} The Fed has begun to scale back these operations by reducing their frequency.

Federal Reserve Liquidity Programs

<u>Program</u>	<u>Rate (bp)</u>	<u>Operation Frequency</u>	<u>Term</u>	<u>Size</u>	<u>Counterparty</u>	<u>Collateral</u>	<u>Termination</u>	<u>Description</u>
Central bank swap lines	OIS+25	Daily and weekly	1w or 84d	Depends on the central bank	Central banks	Local currency collateral and loans	None	Non-US banks can source \$ funding from their local central bank, which in turn gets it from the Fed
Discount window	Primary credit rate (25bp)	Daily	o/n to 90d	Depends on how much collateral is pledged	Banks	a) Loans and investment grade securities b) No equities	None	Traditional lender of last resort program for banks
CP funding facility (CPFF)	a) 3m OIS +110 b) 10bp one time registration fee	Daily	3m	Issuer is limited to the maximum of its outstandings between March 2019-2020	A1/P1 issuers	None	17-Mar-21	a) Fed buys the issuer's CP and holds it to maturity; issuer receives cash b) Treasury is providing \$10bn equity investment in the CPFF SPV for loss protection to the Fed
Primary dealer credit facility (PDCF)	25	Daily	o/n to 90d Prepayments allowed	Depends on how much acceptable collateral the dealer pledges	Primary dealers	IG corporate debt CP (A2/P2) Munis ABS, MBS Equities	At least 6m and possibly longer if conditions warrant	a) Dealers pledge illiquid collateral in return for cash b) Recourse loan (beyond collateral value) to the primary dealer
Money market liquidity facility (MMLF)	a) primary credit +100bp for assets from prime funds b) primary credit+25bp for assets from muni funds	Daily	Maturity matches the maturity of the pledged paper	Depends on how much the acceptable collateral the bank pledges	Banks	a) Prime MMF assets Including A1/P1 CP and AB-CP, along with certain non-TSY/AGY repo	30-Sep-20	a) Banks buy prime fund assets, which they pledge to the Fed in return for cash that they give to the prime fund b) Non-recourse loan to banks, so these assets are excluded from the leverage and RWA capital ratios
FIMA Repo facility	IOER+25bp	as needed	overnight	Depends on how much acceptable collateral the central bank pledges	Central banks and monetary authorities	Treasuries only	at least 6m	Foreign central banks can repo Treasuries to the Fed in return for dollar funding


Re-constituting the 2008 programs

- In the past month, the Fed has re-constituted several liquidity programs from the financial crisis
- These have been modified from their 2008 versions:
 - Lending terms have been lengthened
 - The discount window provides 3m loans
 - There is no frequency limit on the CPFF
 - And the eligible collateral has been expanded
 - The PDCF accepts equities as collateral
- *But some programs appear to be more effective than others^{1/}*

^{1/} Our sense is that the CB swap lines have been the most effective Fed liquidity program to date


Central bank swap lines have loosened offshore funding

Balances (\$bn)



Source: Federal Reserve, Barclays Research

3m cross-currency bases (bn)




Source: Bloomberg, Barclays Research

Why isn't discount window borrowing heavier?

- The Fed lengthened discount window loans to 3m
 - And reduced the primary credit rate to 25bp
- But the program still accepts only investment grade collateral
 - And banks appear to have plenty of cheap financing from the market^{1/}
- *However, they seem less willing to intermediate for clients*

Discount window borrowing (\$bn)



^{1/} For example, non-interest bearing deposits. Term Treasury repo rates have fallen below 25bp.

Source: Federal Reserve, Barclays Research


Rate or balance sheet?

- Is this a question of the rate – that is, are market rates cheaper than Fed-provided financing?
 - Term repo rates have fallen – although they are higher than the 25bp offered for the types of less liquid collateral eligible in the PDCF
- Or does it reflect balance sheet constraints on bank intermediaries?
 - Pledging customer collateral for cash in either program expands the banks' balance sheet
- *If this was only a rate issue, low discount window use would suggest that markets are amply re-liquefied*

Term SOFR rates have fallen

- Term SOFR rates have come down as the Fed's operations have significantly expanded liquidity
 - And balance sheet pressures have eased^{1/}

3m term SOFR less OIS (bp)




^{1/} Balance sheet costs typically add 15bp or more onto the term SOFR-OIS spread, depending on dealer balance sheet availability.

Source: Federal Reserve, Barclays Research

PDCF activity has also been light

PDCF balances (\$bn)



- The PDCF program accepts a wide range of collateral
 - Dealers can pledge securities to the Fed for 3m cash at 25bp
- But, like the discount window, program use has been lighter than expected

Source: Federal Reserve, Barclays Research

Stigma?

- Could banks be reluctant to use the discount window – despite the Fed’s encouragement?
 - The Term Auction Facility – an auction program for discount window loans created during the financial crisis – had more use than the discount window
- Post-crisis disclosure requirements may make banks leery of using any of the Fed’s 13(3) liquidity facilities
 - By law, the Fed is required to publish detailed, transaction-level data on these programs a year after they end^{1/}
 - Most of the Fed’s 13(3) liquidity programs will stop accepting new loans at the end of September 2020
 - And their short-maturities mean the Fed may be publishing transactions data in early 2022

^{1/} See [Liquidity Programs: How much will be disclosed and when?](#), April 2, 2020

Fed credit programs^{1/}

- The Fed's most recent programs have focused on getting credit to small businesses and municipalities
 - These leverage funding provided by the Treasury through the CARES Act
 - And are the first time the Fed is lending to businesses and municipalities
 - Although several of the programs work through banks as “re-distributors” of loan financing
- Several of these programs have yet to be launched

^{1/} For more details on these programs see, [Fed boosts its credit support to '11', with help of Treasury](#), April 9, 2020.

Federal Reserve Credit Programs (1)

<u>Program</u>	<u>Term</u>	<u>Fees</u>	<u>Size</u>	<u>Counterparty</u>	<u>Collateral</u>	<u>Description</u>
Main Street New Loan Facility (MSNLF)	4y loan	a) Eligible lender pays 100bp fee to the Fed on the principal amount of the loan (this can be passed to the borrower) b) The Fed will pay the lender a 25bp servicing fee on the amt of its participation	600bn	US banks and bank holding companies	a) Unsecured loans made to firms with less than 10,000 employees or \$2.5bn in revenue; b) Loan maturities are 4y; c) Amortization of principal and interest deferred for 1y; d) Adjustable rate; SOFR +250-400bp; e) no prepayment fees; f) min size is \$1mn; max size is the lesser of \$25mn or an amount when added to existing debt does not exceed 4x 2019 EBITDA	Fed will provide funding to banks so that they can make small business loans
Main Street New Loan Facility (MSNLF) -- expanded facility	4y loan	see above	included in the \$600bn	see above	a) same collateral and loan terms except the max loan size is the lesser of i) \$150mn, ii) 30% of the borrower's existing debt and undrawn credit lines, and iii) the amount that when added to existing debt does not exceed 6x EBITDA	

Source: Federal Reserve, Barclays Research

Federal Reserve Credit Programs (2)

<u>Program</u>	<u>Rate (bp)</u>	<u>Term</u>	<u>Fees</u>	<u>Size</u>	<u>Counterparty</u>	<u>Collateral</u>	<u>Description</u>
Paycheck Protection Program Liquidity Facility (PPPLF)	35bp	a) Fed loan matches the maturity of the bank's PPP loan; b) PPP loans have a 0 risk weighting and no effect on the bank's leverage ratio; c) there is no haircut; the Fed will lend the bank the full amount of the PPP loan	none	350bn	a) US Banks and some non-bank lenders	Paycheck Protection Program loans guaranteed by the Small Business Administration	Fed will provide funding collateralized with PPP loans that are backstopped by the SBA
Term Asset-Backed Lending Facility (TALF)	2y Libor swap+100bp or 3y Libor swap+100bp ^{1/}	3y loan	a) 10bp administration fee b) Published collateral haircut schedule	100bn	All US companies with eligible ABS collateral	a) New ABS issued after March 23, except for legacy CMBS b) CLOs, CMBs have not been added c) Credit exposures underlying the ABS must be originated (or substantially) by US companies d) SBA pool certificates and development company participation certificates	a) US companies will be able to borrow 3y money from the Fed collateralized with newly issued ABS b) Loans provided are non-recourse to the borrower c) Treasury will make a \$10bn equity investment in all the TALF SPV

^{1/} Depending on the WAL of the underlying assets

Source: Federal Reserve, Barclays Research

Federal Reserve Credit Programs (3)

<u>Program</u>	<u>Rate (bp)</u>	<u>Term</u>	<u>Fees</u>	<u>Size</u>	<u>Collateral</u>	<u>Description</u>
Primary Market Corporate Credit Facility (PMCCF)	Fed will purchase paper from the issuer at a market rate	up to 4y	100bp facility fee	500bn	a) New issue corporate debt rated BBB-/Baa3 or higher; b) Lower rated debt (to BB-) is eligible if the borrower is subsequently downgraded; c) Syndicated loans are eligible; d) Maximum limit per issuer is 130% of the max debt outstanding between 3/22/2019 and 3/22/2020; e) the Fed will not buy more than 25% of the outstanding issue amount	a) The Fed will buy newly issued corp bond directly from the issuer b) Recourse to the issuer c) Treasury will make a \$50bn equity investment in the PMCCF SPV
Secondary Market Corporate Credit Facility (SMCCF)	market price	up to 5y	none	a) 10% single name limit based on the max outstanding between 3/22/19-3/22/20 b) 20% of eligible ETFs' assets as of 3/22/20 c) the Fed will not buy more than 1.5% of the issuer's debt across the PMCCF and the SMCCF	a) Investment grade corporate bonds with remaining maturities of less than 5y b) US listed ETFs with exposure to investment grade and high yield corporates	a) The Fed will buy eligible corporate bonds and ETFs from the secondary market b) Treasury will make a \$25bn equity investment in the SMCCF SPV

Source: Federal Reserve, Barclays Research


Federal Reserve Credit Programs (4)

<u>Program</u>	<u>Rate (bp)</u>	<u>Term</u>	<u>Fees</u>	<u>Size</u>	<u>Counterparty</u>	<u>Collateral</u>	<u>Description</u>
Municipal Liquidity Facility	a) Fed will purchase paper from the issuer; b) Issuer's rating will determine the rate	up to 24m	10bp origination fee based on the principal amount	500bn	a) States, cities, and counties with 1m and 2m residents, respectively; b) size limit of counterparty set at 20% of general revenue from own sources and utility revenue from FY 2017	a) Tax anticipation notes, tax and revenue anticipation notes, and other short-term debt	a) Fed will buy short-term municipal debt from issuers b) the Treasury will provide a \$35bn equity investment into the Municipal Liquidity Facility SPV

Source: Federal Reserve, Barclays Research

How big will the Fed's balance sheet get?


- It is difficult to predict how much demand the Fed will have for either its liquidity and credit programs
 - Our sense is that the liquidity programs are close to their maximums
- If we assume that all the credit programs are maxed out, the Fed's balance sheet could reach or exceed \$9trn by fall



Note: Other includes liquidity programs like the MMLF and open market operations as well as credit programs such as the PMCCF and the TALF. Source: Federal Reserve, Barclays Research

How much bank reserves?

- Bank reserves could be between \$5.5 and 6trn by the end of September
 - From less than \$1.4trn a year-earlier when repo rates spiked
 - As of April 15, bank reserves were \$3.1trn



Source: Federal Reserve, Barclays Research

Balance sheet pressure^{1/}

- All these reserves will take up space on bank balance sheets
 - Choking out bank lending securities purchases
- The Fed has provided some balance sheet relief
 1. In exempting reserves and Treasuries from the supplemental leverage ratio calculation
 2. And exempting bank participation in the money market liquidity (MMLF) and paycheck protection program liquidity facility (PPPLF) from risk and leverage ratio capital assessments^{2/}
- *However, these efforts are meant more to prevent further economic harm than to put banks on the offensive, so that they can make more loans or buy more securities*

1/ For more details, see [Bank regulatory relief, more defense than offense](#), April 15, 2020.

2/ The PPPLF was opened on April 16, 2020.


Bill issuance

Massive bill issuance...

- To raise the cash necessary to finance parts of the CARES Act quickly, the Treasury has ramped up its bill issuance
 - This cash is needed to send out \$350bn in checks to households and to finance the emergency spending required under the CARES Act
 - The Treasury also needs to cover its expenses from having postponed the April 15 tax due date until October
- *We expect the Treasury to need to issue \$825bn in bills this quarter*

...has boosted the Treasury's cash balance

Treasury cash balance (\$bn)




- The cash raised is initially piling up in the Treasury's account at the Fed
 - But this balance will quickly fall over the next few weeks

Source: US Treasury, Barclays Research


Rapid bill expansion...

- In the first three weeks of April, the Treasury has issued more bills than in most full years (nearly \$900bn)
 - Most of this supply has been in cash management bills
 - With late spring and fall maturities
- We expect the Treasury to issue \$1.3trn in bills this year
 - *Although issuance could be larger depending on future stimulus (Phase IV) packages*



Source: US Treasury, Barclays Research

...has cheapened bill yields...




- Heavy bill issuance has already pushed yields up about 15bp
- *Continued heavy issuance could push bill yields 20bp above OIS by summer*

Source: Federal Reserve, Barclays Research

...although the effect has been muted by strong demand

Gov-only fund balances (\$bn)




- A portion (\$300-400bn) of this massive bill issuance has been absorbed by money funds
 - Money funds are experiencing very strong inflows
 - *Although these have started to slacken*

Source: Crane's Data, Barclays Research


Higher bill yields will pull repo rates higher

3m bills and SOFR (%)



Source: Federal Reserve, Barclays Research


Repo and bill spreads (bp)



Note: 20d average. Source: Federal Reserve, Barclays Research

Overnight repo rates have crept higher


- As competition from higher-yielding bills picks up, repo rates have started to creep higher
 - The Fed's reserve expansion and asset purchases have dramatically improved repo market liquidity
 - Which was severely strained in mid-March



Source: Federal Reserve, Barclays Research

Repo volumes are rising

- SOFR volumes continue to rise
 - With the fastest growth in overnight cleared bilateral activity
 - Which accounts for about 60% of daily SOFR volume
- The growth in centrally cleared repo reflects the fact that banks and dealers remain balance sheet sensitive
- *Will changes to the SLR free up more overnight repo balance sheet?*




Source: Federal Reserve, Barclays Research

Commercial paper and LOIS

Commercial paper markets froze in March


- CP issuance froze in March as investors began to hoard liquidity
 - And balances started to flow out of prime funds and offshore money market funds
- Rates moved sharply higher as financial and non-financial issuers struggled to raise money
 - This stress was reflected in LOIS – which widened to over 100bp
 - And remains unusually high



Source: Bloomberg, Barclays Research


CP issuance rose, but maturities shortened...

Daily issuance (\$bn)



Source: Federal Reserve, Barclays Research

Overnight to 4d maturity (% total)




Source: Federal Reserve, Barclays Research

...and the market has shrunk

- As issuers struggled to raise term money, they shifted their borrowing to very short-maturities
 - Daily issuance picked up, but borrowers had more paper to roll each day
- Some issuers decided not to roll their paper
 - And sought other financing
- As a result, outstanding CP volumes are shrinking

Financial CP outstanding (\$bn)



Source: Federal Reserve, Barclays Research

Fed reaction

- The Fed moved quickly to address the seizing up in the CP market
 - Using tools created during the financial crisis, when the market remained frozen for two months^{1/}
- The CPFF allows issuers to raise money by selling CP directly to the Fed
 - The program rate is OIS+110bp, plus a 10bp registration fee
- The MMLF enables banks and dealers to buy assets from money funds using funding provided by the Fed
 - The program allows money funds to sell their less liquid holdings in return for cash that they can use to meet redemptions
 - It prevents asset fire sales

^{1/} AB-CP markets were frozen for much longer, however.

CPFF: Will it work?

- *Will the CPFF work to free up CP markets – and, by extension, LOIS?*
- We expect program demand from banks will be light
 - Banks seem to have plenty of access to financing
 - Whether from the discount window or offshore through the cross-currency basis market and the central bank swap lines
 - Market rates are 1.00-1.15% and, thus, not much more expensive than the Fed's CPFF rate (including the fee)^{1/}
- Unlike 2008, we expect most of the demand for the CPFF to come from large non-financial companies^{2/}
 - Seeking to raise working capital to finance payrolls and operations as the economy is shut down

1/ The registration fee applies to the maximum amount of CP the issuer had outstanding between March 2019 and March 2020.

2/ Outstanding balances on April 15 – its second day – were just under \$1bn.

CPFF: Indirect effects

- We think the CPFF will have two indirect effects on LOIS
 1. It sets the maximum rate for 3m unsecured bank CP (at ~1.17%, excluding the fee)
 2. Early users of the program will be able to lock in funding for 3m
 - And will have less need to roll short-maturity paper
 - As their issuance goes down, we expect other borrowers to be able to come into the market
 - And issue at lower rates


Our sense is that program use will decline sharply when the first 3m paper issued into the program starts to roll off in June

LOIS decline

- CP markets seem to be mending
 - More issuance at longer maturities
 - And rates are coming down
- We look for LOIS to fall to 45bp at the end of June
 - And 25bp at the end of September

MMLF use is light


- The MMLF program allows money funds to sell assets to banks, which use them as collateral for cash loans from the Fed
 - The cash is then passed to the money fund
- Program use has been relatively light
 - *And is expected to fall as no new assets are added to the program and existing holdings mature*



Source: Federal Reserve, Barclays Research

Prime fund balances are stabilizing


- MMLF balances are low because prime fund balances have stabilized
 - Funds have less need to sell assets to raise liquidity to meet redemptions



Source: Crane's Data, Barclays Research

But what will prime fund portfolios look like?

- After the seizing up of the CP market, will money funds resume buying paper?
 - Or will they limit their purchases to only <3m CP?
- Portfolio WAMs have moved higher in recent weeks



Source: Crane's Data, Barclays Research

Terming out

- Given the flatness of the money market curve, we expect money funds (both prime and gov-only) to lengthen their portfolio WAMs
 - To over 50d
- And given the availability of bills, we expect these portfolios to become heavily skewed toward Treasuries

Analyst Certifications and Important Disclosures

Analyst Certification(s)

I, Joseph Abate, hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures:

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays").

All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

Availability of Disclosures:

For current important disclosures regarding any issuers which are the subject of this research report please refer to <https://publicresearch.barclays.com> or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Barclays may have a conflict of interest that could affect the objectivity of this report. Barclays Capital Inc. and/or one of its affiliates regularly trades, generally deals as principal and generally provides liquidity (as market maker or otherwise) in the debt securities that are the subject of this research report (and related derivatives thereof). Barclays trading desks may have either a long and / or short position in such securities, other financial instruments and / or derivatives, which may pose a conflict with the interests of investing customers. Where permitted and subject to appropriate information barrier restrictions, Barclays fixed income research analysts regularly interact with its trading desk personnel regarding current market conditions and prices. Barclays fixed income research analysts receive compensation based on various factors including, but not limited to, the quality of their work, the overall performance of the firm (including the profitability of the Investment Banking Department), the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst. To the extent that any historical pricing information was obtained from Barclays trading desks, the firm makes no representation that it is accurate or complete. All levels, prices and spreads are historical and do not necessarily represent current market levels, prices or spreads, some or all of which may have changed since the publication of this document. Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations and trade ideas contained in one type of Barclays Research may differ from those contained in other types of Barclays Research, whether as a result of differing time horizons, methodologies, or otherwise.

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to <https://publicresearch.barcap.com/S/RD.htm>. In order to access Barclays Research Conflict Management Policy Statement, please refer to: <https://publicresearch.barcap.com/S/CM.htm>.

All pricing information is indicative only. Unless otherwise indicated, prices are sourced from Refinitiv and reflect the closing price in the relevant trading market, which may not be the last available price at the time of publication.

Types of investment recommendations produced by Barclays FICC Research:

In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts in FICC Research. Any such investment recommendations produced by non-Credit Research teams shall remain open until they are subsequently amended, rebalanced or closed in a future research report. Any such investment recommendations produced by the Credit Research teams are valid at current market conditions and may not be otherwise relied upon.

Disclosure of other investment recommendations produced by Barclays FICC Research:

Barclays FICC Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays FICC Research in the preceding 12 months please refer to <https://live.barcap.com/go/research/Recommendations>.

•

.

Important Disclosures Continued

Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)

Barclays Capital Inc. (BCI, US)

Barclays Bank Ireland PLC, Frankfurt Branch (BBI, Frankfurt)

Barclays Bank Ireland PLC, Paris Branch (BBI, Paris)

Barclays Bank Ireland PLC, Milan Branch (BBI, Milan)

Barclays Securities Japan Limited (BSJL, Japan)

Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)

Barclays Capital Canada Inc. (BCCI, Canada)

Barclays Bank Mexico, S.A. (BBMX, Mexico)

Barclays Securities (India) Private Limited (BSIPL, India)

Barclays Bank PLC, India branch (Barclays Bank, India)

Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)

Barclays Bank PLC, DIFC Branch (Barclays Bank, DIFC)

Disclaimer

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been prepared for institutional investors and not for retail investors. It has been distributed by one or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an "institutional debt research report" and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment decisions regarding any debt securities. Media organisations are prohibited from re-publishing any opinion or recommendation concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays institutional debt research reports should contact debtresearch@barclays.com. Clients that are subscribed to receive equity research reports, will not receive certain cross asset research reports co-authored by equity and FICC research analysts that are distributed as "institutional debt research reports" unless they have agreed to accept such reports. Eligible clients may get access to such cross asset reports by contacting debtresearch@barclays.com. Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site ('Third-Party Content'). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results. The information provided does not constitute a financial benchmark and should not be used as a submission or contribution of input data for the purposes of determining a financial benchmark.

United Kingdom: This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

European Economic Area ("EEA"): This material is being distributed in the EEA by Barclays Bank PLC. Barclays Bank PLC is not registered in France with the Autorité des marchés financiers or the Autorité de contrôle prudentiel.

Americas: The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and a Member of the Canadian Investor Protection Fund (CIPF).

This material is distributed in Mexico by Barclays Bank Mexico, S.A. This material is distributed in the Cayman Islands and in the Bahamas by Barclays Capital Inc., which it is not licensed or registered to conduct and does not conduct business in, from or within those jurisdictions and has not filed this material with any regulatory body in those jurisdictions.

Disclaimer (continued)

Japan: This material is being distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokuchō (kinsho) No. 143.

Asia Pacific (excluding Japan): Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585; Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 2267196000. Fax number: +91 22 67196100. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INBI00000950). Barclays Investments and Loans (India) Limited, registered with RBI as Non Banking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth Trustees (India) Private Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this material, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by Barclays Bank PLC or one of the Barclays group entities. None of Barclays Bank PLC, nor such Barclays group entity, holds an Australian financial services licence and instead relies on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001. This material is distributed in New Zealand by Barclays Bank PLC, but it has not been registered, filed or approved by any New Zealand regulatory authority or under or in accordance with the Financial Markets Conduct Act of 2013, and this material is not a disclosure document under New Zealand law.

Middle East: Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

This material is distributed in the United Arab Emirates (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC. Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority. Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi). This material does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe for or purchase, any securities or investment products in the UAE (including the Dubai International Financial Centre) and accordingly should not be construed as such. Furthermore, this information is being made available on the basis that the recipient acknowledges and understands that the entities and securities to which it may relate have not been approved, licensed by or registered with the UAE Central Bank, the Dubai Financial Services Authority or any other relevant licensing authority or governmental agency in the UAE. The content of this report has not been approved by or filed with the UAE Central Bank or Dubai Financial Services Authority. Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

Russia: This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2020). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request. US36277 BRCF2242